Northwestern University Feinberg School of Medicine

Paul Burridge Lab


Read the latest news from the Burridge Lab. The links below take you to articles where you can learn more about our lab’s latest achievements, awards, and honors.


  • New Postdoctoral Fellow Positions Available

    Postdoctoral Fellow Positions Available

    Two postdoctoral fellow positions are available in the laboratory of Dr. Paul Burridge in the Department of Pharmacology and the Center for Pharmacogenomics at Northwestern University Feinberg School of Medicine, Chicago, IL.

    Successful candidates will be involved in projects involving:

    • hiPSC-derived cardiomyocytes and endothelial cells to model the genomic basis of chemotherapy-induced toxicity
    • hiPSC-derived cardiomyocytes to model the genomic basis of arrhythmias and sudden cardiac death.
    • Cardiac organoid models of cardiac structural disease
    • Development of very large-scale iPSC differentiation
    • Skeletal muscle and adipose differentiation
    • Cardiac regenerative medicine (cardiac engraftment and direct reprogramming)

    Desirable expertise includes: iPSC reprogramming, iPSC culture, differentiation methodologies, CRISPR, bioreactors, hiPSC disease modeling, bioinformatics, genomics, eQTL, GWAS, drug response assays, chemotherapy drug response/toxicity mechanisms.

    Good verbal and written communication skills in English are essential. The successful candidate will join a dynamic research environment in the Department of Pharmacology, which offers both basic science and clinical translational opportunities to explore fundamental questions in pharmacogenomics. More details can be found here:

    Starting salary will be according to NIH (NRSA) scale and commensurate with experience.

    Please send a CV (including publications), a cover letter containing a brief description of research experience and interests, and a list of 2-3 references to:

    Northwestern University is an Equal Opportunity, Affirmative Action Employer of all protected classes, including veterans and individuals with disabilities. Women and minorities are encouraged to apply. Hiring is contingent upon eligibility to work in the United States.

    The positions will remain open until filled. 

  • Burridge Lab Awarded Second R01
    The Burridge lab has been awarded a second R01. In this grant, funded by the National Cancer Institute, we will study the genomics of anthracycline cardiotoxicity in African American children in collaboration with St. Jude Children's Research Hospital in Memphis.
  • Tarek's Review "Use of hiPSC to Explicate Genomic Predisposition to anthracycline-Induced Cardiotoxicity" Published

    Use of hiPSC to Explicate Genomic Predisposition to Anthracycline-Induced Cardiotoxicity


    The anticancer agents of the anthracycline family are commonly associated with the potential to cause severe toxicity to the heart. To solve the question of why particular a patient is predisposed to anthracycline-induced cardiotoxicity (AIC), researchers have conducted numerous pharmacogenomic studies and identified more than 60 loci associated with AIC. To date, none of these identified loci have been developed into US FDA-approved biomarkers for use in routine clinical practice. With advances in the application of human-induced pluripotent stem cell-derived cardiomyocytes, sequencing technologies and genomic editing techniques, variants associated with AIC can now be validated in a human model. Here, we provide a comprehensive overview of known genetic variants associated with AIC from the perspective of how human-induced pluripotent stem cell-derived cardiomyocytes can be used to help better explain the genomic predilection to AIC.

  • Hana's Review "Cellular Model Systems to Study Cardiovascular Injury from Chemotherapy" Published

    Cellular Model Systems to Study Cardiovascular Injury from Chemotherapy



    In spite of all the efforts for generating efficient pharmacological treatment options for cancer patients, the unwanted side effect of these substances on the cardiovascular system is becoming a major issue for cancer survivors. The fast pacing oncology field necessitate the quest for more accurate and reliable preclinical screenings. hiPSCs derived cardiomyocytes, endothelial and vascular smooth muscle cells provide unlimited source of physiologically relevant cells that could be used in the screening platforms. Cells derived from hiPSCs can measure drug induced alterations to different aspect of the heart including electrophysiology, contractility and structure. In this review, we will give an overview of the different in vivo and in vitro preclinical drug safety screenings. In following sections, we will focus on hiPSCs derived cardiomyocytes, endothelial and vascular smooth muscle cells and present the current knowledge of the application of these cells in unicellular cardiotoxicity assays. In the final part, we will focus on cardiac organoids as multi cell type platform and their role in cardiotoxicity screening of the chemotherapeutic drugs.

  • Davi's review on hiPSC models for chemotherapy-induced toxicity published in Current Cardiology Reports

    Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity



    Purpose of review: In this article, we review the different model systems based on human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and how they have been applied to identify the cardiotoxic effects of anticancer therapies.

    Recent findings: Developments on 2D and 3D culture systems enabled the use of hiPSC-CMs as screening platforms for cardiotoxic effects of anticancer therapies such as anthracyclines, monoclonal antibodies, and tyrosine kinase inhibitors. Combined with computational approaches and higher throughput screening technologies, they have also enabled mechanistic studies and the search for cardioprotective strategies. As the population ages and cancer treatments become more effective, the cardiotoxic effects of anticancer drugs become a bigger problem leading to an increased role of cardio-oncology. In the past decade, human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have become an important platform for preclinical drug tests, elucidating mechanisms of action for drugs, and identifying cardioprotective pathways that could be further explored in the development of combined treatments. In this article, we highlight 2D and 3D model systems based on hiPSC-CMs that have been used to study the cardiotoxic effects of anticancer drugs, investigating their mechanisms of action and the potential for patient-specific prediction. We also present some of the important challenges and opportunities in the field, indicating possible future developments and how they could impact the landscape of cardio-oncology.

    Keywords: Anticancer therapy; Cardio-oncology; Cardiomyocyte; Cardiotoxicity; Chemotherapy; Human induced pluripotent stem cell.